Singapore AI Helps Drugs Work Without Past Data

Finding new medicines just got faster thanks to a breakthrough from Singapore researchers who taught AI to think beyond its training wheels.

A team from Nanyang Biologics presented their Test-time Adaptation (TAB) framework at a major AI conference in April 2026. The system solves a problem that's been frustrating drug researchers for years: AI models that freeze up when they encounter molecules or proteins they've never seen before.

Think of it like teaching someone to cook only Italian food, then asking them to make Thai curry. Most AI systems would fail. TAB helps them adapt on the spot.

The pharmaceutical industry has struggled with this limitation because discovering new drugs means exploring unknown territory by definition. Previous AI models could only make accurate predictions about molecules similar to their training data. Anything genuinely novel threw them off course.

The Singapore team, led by researchers Yiming Yang, Zhiyuan Zhou, and Yueming Yin working with Associate Professors Hoi-Yeung Li and Adams Wai-Kin Kong, built something smarter. Their framework focuses on what actually matters: how a drug molecule physically fits into pockets on target proteins.

TAB uses a clever trick to avoid false patterns. It randomly masks parts of molecules to force the AI to focus on the actual binding regions where drugs do their work, not coincidental features that appeared often in training data but don't cause any real effect.

The system runs each prediction multiple times with slight variations, measuring consistency. Reliable answers get more weight. Wild guesses get ignored. This prevents the AI from confidently making terrible predictions.

The Ripple Effect

Early testing shows impressive results. Across eight different test scenarios, TAB improved prediction accuracy by 8.2% and ranking consistency by 5.8% compared to the best existing methods.

The breakthrough means drug researchers can now share AI models across companies and labs without exposing proprietary data. That's been a major roadblock to collaboration in pharmaceutical research, where trade secrets are closely guarded but shared intelligence could save lives.

Nanyang Biologics has already filed a provisional patent and incorporated TAB into Vecura, their AI platform for molecular discovery. The technology could speed up the entire drug development pipeline, potentially bringing new treatments to patients years earlier than traditional methods allow.

For patients waiting for therapies that don't exist yet, this kind of progress transforms hope into something more tangible.

#